摘要
目的:检测Aurora B激酶在原发性上皮性卵巢癌组织中的表达情况,探讨其在卵巢癌发生发展中的意义。方法:用免疫组织化学PV二步法测定Aurora B蛋白在卵巢癌(n=61)、良性卵巢肿瘤(n=20)及正常卵巢(n=15)组织中的表达。并对所有卵巢癌患者进行随访,探讨Aurora B表达水平的临床意义。结果:原发性上皮性卵巢癌组织中Aurora-B蛋白阳性表达率(77.05%)显著高于良性卵巢肿瘤组织(25.00%)及正常卵巢组织(6.67%)(P=0.000)。Aurora-B蛋白表达水平与临床手术分期及病理分级有关(P=0.000,P=0.017),而与组织类型及有无淋巴结转移无关(P=0.978,P=0.795)。单变量分析结果显示,Aurora-B与原发性上皮性卵巢癌复发有关。多变量分析结果显示,Aurora-B是影响患者复发的独立因素(P=0.000)。结论:Aurora-B蛋白的过度表达与上皮性卵巢癌的预后有关,有望成为观察患者预后的指标之一。
Objective：To explore the expression of Aurora B in primary epithelial ovarian earcinoma and evaluate its clinical significance. Methods： Immunohistochemistry method （PV method） was used to detect the expression of Aurora-B protein in 61 primary epithelial ovarian carcinoma,20 benign epithelial ovarian tumor tissues and 15 normal ovarian tissue sampies. Every patient with primary epithelial ovarian carcinoma was followed up, to explore the clinical significance of Aurora-B expression. Results：The positive expression rate of Aurora-B protein in primary epithelial ovarian carcinoma was significantly higher than that in benign ovar- ian tumor and normal ovarian tissue（P=0.000）. The positive rate were 77.05% ,25.00% and 6.67% ,respectively. The expressions of Aurora-B protein was associated with the FIC, O stage, and histological degree of epithelial ovarian carcinoma tissue （ P = 0.000, P = 0.017） ; but not associated with histologic type and lymph node metastasis （ P = 0. 978, P = 0.795）. Using the uniariate analysis,Aurora-B was relevant with primary epithelial ovarian carcinoma recurrence. Using the multiariate analysis it was the independent factor for patients with recurrence （P=0.000）. Conclusion：Aurora-B may be a prognostic factor and a new therapeutic target for epithelial ovarian carcinoma.
出处
《现代妇产科进展》
CSCD
2013年第11期888-891,共4页
Progress in Obstetrics and Gynecology
